HEARTBiT, a blood-based transcriptomic biomarker, reliably detects moderate-to-severe acute cellular rejection (ACR) after heart transplantation across the first post-operative year.
The biomarker maintains high diagnostic accuracy early post-transplant (≤60 days) when rejection risk is greatest, showing an AUC of 0.78 and sensitivity up to 89%.
HEARTBiT enables safe reduction of invasive endomyocardial biopsies, sparing over 50% of routine surveillance biopsies without significantly increasing missed rejection cases.
Serial tracking of HEARTBiT scores demonstrates prognostic potential by rising weeks before histological biopsy detection of rejection, enabling earlier intervention possibilities.
